ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Incannex Healthcare kicks off Phase 2 rheumatoid arthritis trial

Incannex Healthcare Ltd (ASX:IHL, NASDAQ: IXHL) CEO Joel Latham tells Proactive the company has begun a Phase 2 clinical trial, testing the safety and efficacy of its IHL-657A drug candidate in patients with rheumatoid arthritis. Research firm Avance Clinical will manage the trial across up to 10 sites in Australia and New Zealand, overseeing responses from 120 participants as they evaluate how IHL-657A treats patient pain and function over 24 weeks.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

Jonathan@proactiveinvestors.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  223.16
-7.14 (-3.10%)
AAPL  271.23
+1.53 (0.57%)
AMD  256.59
-7.74 (-2.93%)
BAC  52.95
+0.37 (0.69%)
GOOG  283.58
+8.41 (3.06%)
META  666.32
-85.35 (-11.35%)
MSFT  523.56
-17.99 (-3.32%)
NVDA  202.03
-5.01 (-2.42%)
ORCL  257.69
-17.61 (-6.40%)
TSLA  442.14
-19.37 (-4.20%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.